New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Radiopharm Theranostics Limited - Sponsored ADR

RADX

Healthcare Biotechnology

Radiopharm Theranostics Limited - Sponsored ADR’s revenue for fiscal 2026 (year ended June 2026) was $1.9 million, down 20.2% from fiscal 2025.

0.63 0.04 −5.97%

After hours trading: 0.60, down 4.76%, last trade Fri 4:27pm Eastern.

Market cap
$10.6M
P/E
—
Fwd P/E FY27e
—
Dividend yield
—
F-score
3/9
ROIC
—
Net debt / EBITDA
0.1×
Payout ratio
—

Radiopharm Theranostics Limited - Sponsored ADR (RADX) news

The news and the share price important stories, numbered as below

Share price since Oct 22 −33.6%

Stories the last two months, newest first

  1. Results ·

    Radiopharm reports interim RAD101 imaging results in 32 participants

    Among 32 participants, RAD101 PET/CT showed 93.5% patient-level agreement with contrast-enhanced MRI; preliminary sensitivity was 85.7% among 16 participants evaluable against a reference standard. No serious treatment-emergent adverse events or clinically significant laboratory or ECG abnormalities were observed. Full diagnostic accuracy results are expected in 2027.

    Reported by Globe Newswire

  2. 1 Other ·

    Radiopharm aligns with FDA on a single pivotal RAD101 Phase 3 trial

    Radiopharm Theranostics received final FDA meeting minutes aligning on a single pivotal Phase 3 trial of RAD101 to distinguish recurrent brain metastases from treatment effects. The multicenter study will enroll about 280 patients and assess sensitivity and specificity against a defined reference standard. The company expects to select a CRO in Q4 2026 and begin site activations and dosing in the first half of 2027.

    Reported by GlobeNewswire

More headlines